Syngene International Ltd – Detailed Stock Analysis Report (November 2025)
Technical Chart Analysis
Syngene’s stock is currently showing a moderately bullish trend. The price is trading above its key moving averages, including the 20-day and 50-day exponential moving averages (EMA), signaling short- to medium-term strength. The Relative Strength Index (RSI) is around 60, indicating healthy buying momentum without being overbought. MACD (Moving Average Convergence Divergence) is positive, supporting bullish momentum. The stock has strong support near ₹650 and faces resistance around ₹685–₹700. Volume trends show consistent participation, confirming buyer interest. Given this technical setup, Syngene looks poised for a gradual uptrend, with cautious monitoring near resistance zones.
Fundamental Analysis
Syngene International is a leading contract research and manufacturing organization (CRAMS) in India, serving global pharmaceutical and biotechnology companies. The company’s revenue in the last quarter (Q2 FY26) was ₹911 crore, growing modestly by 2% YoY, while EBITDA declined 18% primarily due to inventory correction in the CDMO (Contract Development and Manufacturing Organization) segment. Reported PAT dropped 37%, reflecting short-term pressure on profitability. However, long-term prospects remain positive due to robust pipelines in biologics, strategic expansions, and investments in peptide capabilities. Syngene’s strong client relationships, expanding service segments, and operational efficiencies bode well for future growth. The stock currently trades at a high P/E multiple (~57x), implying expectations of future earnings growth.
Recent News & Upcoming Event
Syngene’s management will hold an analyst call to discuss Q2 FY26 results.
Participation in upcoming international pharma conferences (e.g., CPHI India in November 2025).
Announced strategic focus on biologics, peptide APIs, and novel drug delivery systems.
Market analysts suggest cautious optimism due to recent margin contraction but emphasize long-term growth potential.
Positive Points
Leadership position in Indian CRAMS with global clientele.
Diversification into biologics and specialty peptides increasing growth visibility.
Strong cash flows, low debt, and healthy balance sheet.
Ongoing innovation and investment into newer service platforms.
Negative Points
Recent margin contraction impacting short-term profitability.
Moderate revenue growth amid inventory corrections.
High valuation may limit near-term upside without earnings acceleration.
Dependency on global pharma industry cyclicality and contract renewals.
Disclaimer & Disclosure
This analysis is for informational purposes only and does not constitute a buy or sell recommendation. Stock investments carry risk and market volatility. Investors should perform due diligence and consult a registered financial advisor prior to making investment decisions. No personal or organizational stake is held in Syngene International by the author.